Our genes affect how we react to medications. A drug that works for one person, can be ineffective or cause side effects for another. With pharmacogenetic testing your doctor can predict your response to different drugs and offer safer and more effective medication for you individually. Pharmacogenetic testing enables precision medication in e.g. cardiology, neurology and psychiatry.
Scientific evidence shows that clinically significant adverse drug reactions (ADR) are reduced by 30% if the attending physician has the results of a pharmacogenetic test to support medication decision-making.
Healthcare providers and laboratories offer pharmacogenetic testing. You can also use our home sample collection kit.
We at Abomics support doctors in daily clinical decision-making. The Abomics pharmacogenetic interpretation service enables laboratories to complement DNA test results with an interpretation report that is designed for doctors. The pharmacogenetic interpretation report includes clear recommendations for determining a drug and dosage that is suitable for the patient in question. Together with our subsidiary Multirec, we also offer medical databases on pharmaceuticals, drug indications, drug-drug interactions, pharmacogenetic gene-drug interrelationships etc. These databases are available for integrations with electronic health record (EHR) and prescription systems and other software and databases. The databases support doctors’ decision-making and enable smooth and efficient prescription and medication evaluation workflows. Database information enables evidence-based, effective, and efficient decision-making in clinical practice and supports effective and safe medication.
Abomics has appointed Andrea Izquierdo Bouldstridge as Lead Bioinformatician. Andrea strengthens the company’s expertise in bioinformatics and genomics and supports the continued development of clinically actionable pharmacogenetic solutions. Andrea holds a background in Biology, an MSc in Bioinformatics, and a PhD in Human Genetics. Throughout her career, she has developed extensive expertise in genetics and...
Turku, Finland, 18. May 2025 The Abomics team has been strengthened with a new addition, as MD Nora Nikander has joined our Medical Advisory team. She previously worked as a physician at Turku University Hospital. Nora has a strong interest in personalized medicine and pharmacogenetics, and she brings with her valuable clinical expertise. In her...
Turku, Finland, May 23, 2025 – Abomics is pleased to share updates to its leadership and team structure as the company continues to grow and strengthen its position in the field of precision medicine. Henriikka Halinen has been appointed Chief Commercial Officer at Abomics. Henriikka brings more than 20 years of experience in health technology,...
Abomics Oy is a Finnish company specialised in offering tools to support doctors’ decision-making. We are based in Finland and offer pharmacogenetic solutions for clinical laboratories, healthcare providers and healthcare IT and software companies.